Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis
Introduction: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in pancreatic neuroendocrine neoplasms (pNENs).
Aim(s): This is an Italian multicenter retrospective analysis to evaluate activity and toxicity of CAP-TEM regimen in patients with advanced NENs and potential correlation with some biological factors.
Materials and methods: Clinical records of patients from 4 centers were reviewed. Objective response rate (ORR = PR+SD), and toxicity were calculated. The MGMT methylation-status (MGMT-gene > 5% = responders) and TS-polymorphisms (2R/2R, 2R/3R = responders) in tumor tissue/peripheral-blood were evaluated by pyrosequencing.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Spada F
To read the full abstract, please log into your ENETS Member account.